PYOGENIC LIVER ABSCESS Dr B Ramdas Rai Prof
PYOGENIC LIVER ABSCESS Dr. B. Ramdas Rai Prof. & Unit Chief YMCH
• Aetiology 1. Biliary sepsis: a. Empyema gallbladder. b. Cholangitis. c. After biliary tract surgery. d. Instrumentation. 2. Portal vein sepsis: a. Appendicitis. b. Diverticulitis
3. Distant infections: a. Pneumonia. b. Upper U. T. I. c. Endocarditis. 4. Super added infections: a. Amoebic liver abscess. b. Hydatid cyst. 5. Cryptogenic liver abscess—No identified primary infection. 6. Trauma becoming common cause.
Causative bacteria • E. coli—commonest • Klebsiella • Proteus • Pseudomonas • Clostridia
• Clinical Features • Pain in the right hypochondrium. • High fever, with rigors. • Weight loss. • Jaundice—occasionally. • Inter-costal tenderness. • Tender, soft liver. • Features of toxicity
Diagnosis • Ultrasound abdomen, CT scan. • LFT, total count. • Ultrasound guided aspiration of pus after controlling prothrombin time.
Treatment • Systemic antibiotics—combination of third generation cephalosporins and metronidazole. • Ultrasound guided aspiration/pigtail catheter. • Occasionally open drainage is required. • Treating the primary causes is very essential.
Complications • Septicaemia, liver failure. • Rarely rupture & peritonitis can occur. • Klebsiella hepatic abscess can cause dangerous endogenous endophthalmitis commonly in diabetic patients impairing vision.
Dr. B. Ramdas Rai Prof. & Unit Chief YMCH
FORMATION q Portal vein is formed by confluence of SMV and Splenic vein q behind the neck of pancreas q at the level of L 1 or L 2 Portal vein is formed by confluence of SMV and Splenic vein behind the neck of pancreas at the level of L 1 or L 2
Anatomy of portal circulation • 5 – 8 cm long • 0. 8 cm diameter • Its main tributaries -Left gastric -Pyloric -Cystic -Pancreaticoduodenal
Contd… • In porta hepatis portal vein divides into two branches which goes to each lobe • Open into sinusoids • Empty into central veins • Sublobular veins • Interlobular veins • Hepatic vein -3 in no • IVC
PHYSIOLOGY OF PORTAL CIRCULATION • Hepatic blood flow – 1500 ml/min (25% of cardiac output) • Portal vein contributes 2/3 rd of the total hepatic blood flow • Hepatic arterial perfusion accounts for more than 50% of the livers oxygen supply
Contd… • Portal vein is a valveless structure resistance to Portal Blood Flow(at any level between right side of heart to splanchnic vessels) retrograde flow of blood from high pressure Portal Venous System to low pressure systemic venous circulation
DEFINITION
PATHOPHYSIOLOGY • Portal hypertension results from changes in portal resistance in combination with changes in portal inflow. • Ohm’s law is V = IR, where V is voltage, I is current, and R is resistance. This can be applied to vascular flow; ie, P = FR, where P is the pressure gradient through the portal venous system, F is the volume of blood flowing through the system, and R is the resistance to flow • This states that increases in portal resistance or portal flow can contribute to increased pressure. • Portal hypertension almost always results from increases in both portal resistance and portal flow
PATHOPHYSIOLOGY Role of Nitric Oxide in Portal Hypertension -NO is produced in the vascular endothelium from Larginine -It is a gas with a very short half-life -It is a local vasoactive factor -In vascular smooth muscle cells, NO induces a reduction of vascular tone. -Using inhibitors of NOS, have shown that an overproduction of NO contributes to portal hypertension
Zones of Gastro –Esopageal Varices 1)Gastric Zone : 2 -3 cms below the GE junction where the veins join & drain into short gastric & left gastric veins 2)Palisade Zone: Which extends for 2 to 3 cms in the lower esophagus 2)Perforating Zone: Where the network of submucosal veins connects via perforating veins the periesophageal veins. These perforating veins normally have valves that direct blood into the periesophageal veins. In portal hypertension, the valves of the perforating veins are incompetant & allow retrograde flow 4)The Truncal Zone: which is approximately 10 cms long & has 4 longitudinal venous columns.
PATHOPHYSIOLOGY • SEQUENCE OF EVENTS ü Block to portal flow leads to increased portal pressure ü Splanchnic vascular bed response - initial vasoconstrictor - secondarily vasodilator response ü Collaterals develop ü Plasma volume expansion
Porto systemic collaterals-Sites Veins around 1)Cardio oesophageal junction (esophago gastric varices) 2) Periumbilical or abdominal wall collaterals 3)Retroperitoneal veins 4) Rectum (haemorrhoids) 5) Bare area of the liver
Clinical Features • Variceal bleeding • Ascites • Encephalopathy
ETIOLOGY OF PORTAL HYPERTENSION
Portal Vein Thrombosis • Most common cause of Pre hepatic portal hypertension • Can be -Congenital - Sepsis - Trauma Accounts for almost 50% of cases of portal hypertension in childern
Contd… • When portal vein is thrombosed in the absence of liver disease, hepatopetal portal collaterals develop to restore portal perfusion • This combination is termed as cavernomatous transformation of the portal vein
Schistosomiasis • Schistosomiasis (also known as bilharzia caused by several species of trematodes (platyhelminth infection, or "flukes"), a parasitic worm of the genus Schistosoma hematobium. • Snails serve as the intermediary agent between mammalian hosts. • Individuals within developing countries who cannot afford proper water and sanitation facilities are often exposed to contaminated water containing the infected snails.
• After penetration of the skin, the schistosomulum travels to the lungs • It undergoes further developmental changes necessary for subsequent migration to the liver. • Eight to ten days after penetration of the skin, the parasite migrates to the liver sinusoids. • During this period that the parasite begins to feed on red blood cells. • Once fully formed they cause the congestion of the sinusoids leading to portal hypertension
Budd Chiari Syndrome • Budd-Chiari syndrome is a rare cause of postsinusoidal liver failure and cirrhosis, • The pathophysiology is related to thrombosis of the three major hepatic veins at the level of the inferior vena cava. • There may also be an associated web in the vena cava.
• The disease is more common in women and is associated with a variety of hypercoagulable states: ü protein C, S, or antithrombin III deficiency; polycythemia vera; ü estrogen exposure; ü myeloproliferative disorders.
Budd Chiari Syndrome CLINICAL PRESENTATION 1)Acute Form – Nausea, vomiting, severe pain in right hypochondrium, rapid enlargement of liver 2)Less sudden form – Rapid development of ascites, hepatic insufficiency, pedal edema 3)Chronic Type – Hepatic cirrhosis, ascites, oesophageal varices, infection- hepatic failure
• Transcutaneous Doppler-flow ultrasound will show thrombosed hepatic veins and may demonstrate large collaterals into the inferior vena cava. • CT findings include striking caudate lobe hypertrophy and inhomogeneous contrast enhancement. • Anticoagulation is the standard immediate therapy. • Liver transplantation is appropriate for patients with advanced liver disease, but is plagued by potential failure resulting from the underlying disorder
• Most common cause of portal hypertension in children – Portal vein thrombosis (PVT) • In PVT- Blood flow to liver maintained by collateral blood vessels ( cavernomatous transformation of portal vein
LEFT SIDED PORTAL HYPERTENSION : • Etiology : Due to isolated splenic vein thrombosis (secondary to pancreatic inflammation or neoplasm) • Clinical Features- Gastric varices • Cure can be achieved by a splenectomy
EVALUATION • Based on : ü Assessment of the liver disease ü Assessment of the portal circulation ü Upper gastro-intestinal endoscopy
HISTORY • Alcoholism • Hepatitis • Chronic biliary disease EXAMINATION • Jaundice • Ascites • Encephalopathy • Malnutrition • splenomegaly
Multidisciplinary Approach • • Hepatologists Gastroenterologists / Endoscopists Surgeons Radiologists Pathologists Critical Care Staff / Anaesthetists Nurse Clinicians / Support Team
INVESTIGATIONS AIM: a. To find cause of portal hypertension. b. To identify hepatic reserve. c. To define vascular anatomy. d. To find cause for GI hemorrhage
LABORATORY TESTS Liver function test : ü Hypoalbuminemia indicates chronic liver disease. ü Increased aspartate aminotransferase, alanine aminotransferase indicates ongoing hepatocellular necrosis. ü Increased alkaline phosphatase indicates intra/extra hepatic cholestasis. ü Increased PT and Bilirubin indicates hepatic decompensation. ü Serology for hepatitis B and C virus.
• Serum electrolytes : 1) Hypokalemia, 2)Hyponatremia and 3)Metabolic alkalosis secondary to diarrhoea and recurrent emesis. Consequences: Impairs tissue oxygen delivery Converts NH 4 cl to NH 3 - Hepatic encephalopathy
The two main scoring systems for liver disease severity are: • Child Pugh Score • Model for End Stage Liver Disease(MELD)
CHILD- PUGH CLASSIFICATION Measure Serum bilirubin Serum albumin PT prolongatio n Ascites Neurologic disorder 1 2 <2 2 -3 >3. 5 1 -3 sec. 2. 8 -3. 5 4 -6 sec. 3 >3 <2. 8 >6 sec. None Slight Moderate None Minimal Advanced
• MELD Score = 0. 957 x loge creatinine(mg/dl) + 0. 378 x loge bilirubin (mg/dl) + 1. 120 loge INR
Class determined on the basis of total points scored: 5 to 6 points - class A 7 to 9 points - class B 10 to 15 points - class C MELD Score Good Risk Patient <10 Indeterminate patient 10 to 16 End Stage Liver Disease >16
IMAGING • • Ultrasound CT/MRI Doppler ultrasound Liver Biopsy
CT Angiogram Portal venous anatomy
Hepatic Venous Pressure Gradient • Portal pressure is measured indirectly from hepatic veins • Difference between wedged & free hepatic vein pressures = HVPG • Done with a balloon occlusion technique similar to Swan Ganz measurement in pulmonary circulation • Normal HVPG= 6 to 8 mm. Hg
ESOPHAGEAL VARICES
Haemorrhage Fundal varices with Portalgastropathy
VARICEAL HAEMORRHAGE • Life threatening complication of portal hypertension • 30% of patients with cirrhosis develop portal hypertension • 30% of patients with portal hypertension will bleed from varices within 2 years
PATHOPHYSIOLOGY • Laplace’s Law The tension on the wall of a sphere = Pressure X Radius of the chamber and the tension is inversely related to the thickness of the wall. • Application – Variceal wall tension is directly related to transmural pressure and varix radius and inversely related to variceal wall thickness, thus combining all three of these variables
Staging Systems • Italian Endoscopic Staging • Japanese Staging • Sarins Staging
Italian Endoscopic Staging • Grade 1 – Minimal varices without luminal prolapse <30% • Grade 2 – Large varices with luminal prolapse & with moderate obscuring of OG junction 3060% • Grade 3 – Very large varices, with luminal prolapse & with complete obscuring or OG junction >60%
Japanese Staging • In this classification the oesophageal varices are described by 1)The extent(distance of from GE in cms) 2)Size (F 0 -no varices, F 1 small & non tortuous, F 2 - tortuous but less than 50% radius, F 3 large & tortuous 3)Color (blue or white) 4)Presence of red signs (red wale markings, cherry red spots, hematocystic spots)
Sarins Classification GOV 1 – Gastro-oesophageal varices extending down the lesser curvature, more or less straight GOV 2 – Gastro-esophageal varices extending into the fundus of stomach, long & tortuous IGV 1 - Isolated gastric varices in the fundus IGV 2 - Isolated ectopic varices at other sites in stomach & duodenum
MANAGEMENT The therapies available for treating variceal bleeding are: • Pharmacotherapy • Endoscopic therapy • Decompressive shunts – radiologic or surgical • Devascularisation operations • Liver transplantation
PHARMACOTHERAPY • It plays an important role in: ü ü ü Preventing the initial bleed Managing the acute variceal bleed As first line treatment in preventing rebleeding
PHARMACOTHERAPY • • Beta blockers- Inderal, Nadolol Vasopressin Octereotide Terlipressin Nitrates Serotonin antagonists Calcium channel blockers
PHARMACOTHERAPY • • Beta blockers- Inderal, Nadolol Used since 1980’s in prophylaxis Also used as intial therapy in rebleeding Patients with moderate to large sized varices should be placed on these Dose • Inderal- 20 mg/12 hrs • Nadolol- 10 mg/day
PHARMACOTHERAPY • Vasopressin was the 1 st drug used in acute variceal bleeding– 20 units in 100 ml 5% glucose Iv over 10 mins, repeated 3 to 4 times at hourly intervals • Somatostatin & its analogues- 250 microgram as bolus followed by 250 microgram/hr for 2 to 5 days • Octreotide (50 ug/hr) • Terlipressin- 2 mg IV 6 th hrly till bleeding stops, 1 mg 6 th hourly for further 24 hrs
• Patients who have more than >20% reduction in their Hepatic Venous Pressure Gradient or Who reduce their Hepatic Venous Pressure Gradient to <12 mm. Hg will not bleed
Endoscopic Therapy • Most commonly used therapy, controls bleeding in 85% of patients Methods Sclerotherapy Band ligation
Sclerotherapy • Sclerosants used: ü Sodium tetradecyl sulphate, ü Polidocanol, ü Sodium morrhuate, ü Ethanolamine oleate, ü Absolute alcohol ü Cyanoacrylate glue for gastric varices • Technique : Intravariceal ligation Paravariceal ligation Combined
Intravariceal injection of esophageal varices
Paravariceal injection
Combined intra and paravariceal ligation
Complications : -Esophageal ulceration -Esophageal perforation, -Worsening of variceal haemorrhage
Band ligation • More effective • Fewer complicati ons
Steps Varix drawn into ligator by suction
Band applied
Balloon Tamponade • Sengstaken-Blakemore tube Minnesota tube § Consists of 3 tubes & 2 baloons • Disadv 1)Frequent recurrent haemorrhagege • 2)Discomfort to patient 3)Oesophageal perforation 4)Ischaemic necrosis of oesophagus
Modified Sengstaken Blakemore tube
Transjugular Intrahepatic Portosystemic Shunt(TIPS) Indications : 1) Short term bridge to liver transplantation in patients with recurrent bleeding , poor liver function. 2)As definitive therapy in acute bleeding not controlled by less invasive treatment. Disadvantages • It is a non-selective shunt • Shunt stenosis or occlusion develops in 50% of patients with in one year
TIPS - Steps
1)Done under LA and sedation 2)A guide wire is inserted via Right Internal Jugular vein, Superior Venecava and into a hepatic vein
3)The needle is punctured through hepatic parenchyma to enter the main Right portal vein
4)This parenchymal tract is then dilated with a baloon catheter placed over guide wire
5)Finally metallic stent is placed in dilated parenchymal tract thus creating the shunt
TIPS as seen on an angiographic study after stent placement
Complications • Restenosis • Thrombosis • Early Thrombosis – Bile duct puncture • Late stenosis – Most commonly occurs at the hepatic vein end
DECOMPRESSIVE SHUNTS • This mode of management has changed dramatically over last 2 decades. • Considered as second line treatment • Reserved for patients who rebleed through endoscopic banding & beta blockers or whose varices remain “high risk”
SHUNT PROCEDURES • MOA Decompress portal venous system by shunting portal blood into low pressure systemic circulation • Complications : Portosystemic encephalopathy Accelerated hepatic failure
Porto systemic shunts Depending on whether they completely decompress, compartmentalize or partially decompress- v. Non selective (Total) v. Selective v. Partial
Non selective shunts
End to Side Anastomosis (Eck Fistula) § Portal vein divided close to liver § Lower end anastomosed to side of IVC § Decompresses portal hypertension § Does not relieve ascites
Side to side anastomosis • Portal vein and IVC are connected in side to side fashion • Shunts – 12 to 15 mm • Intact upper end of the portal vein Indication -To relieve ascites -Prevent recurrent variceal bleed
Interpositional shunts • Synthetic graft or autologous vein is interposed between portal and systemic venous circulation • Three types Portocaval Mesorenal
Contd… ADVANTAGE-Easy to reconstruct -Hepatic hilum avoided -Easily occluded if intractable post shunt encephalopathy develops DISADVANTAGEHigh graft thrombosis rate
CONVENTIONAL SPLENORENAL SHUNT • Anastomosis of proximal splenic vein to left renal vein after performing splenectomy • Adv – Hypersplenism avoided • Disadv Shunt thrombosis common (small prox. vein)
Selective shunts • Distal splenorenal shunt (Warren’s shunt) • Left Gastric Venecaval shunt (Inokuchi shunt)
Distal Spleno Renal Shunt • Separate splenic vein from posterior surface of pancreas, • Interrupt all major collaterals • Splenic vein is ligated at junction with portal vein portal end ligated • Distal splenic end anastomosed to left renal vein
ü Selectively decompresses the gastroesophageal varices ü Most Commonly used in Child’s Class A & B ü Results in separation of portal venous circulation into a decompressed gastrosplenic venous circuit & high pressure superior mesentric venous system continues to perfuse the liver
• Contraindications for Warren shunt ü Presence of ascites ü Splenic vein diameter <7 mm ü Prior splenectomy • Warren shunt becomes non selective in patients with alcoholic cirrhosis due to pancreatic collateral network which can be avoided by splenopancreatic disconnection
Partial shunts • Objectives -Preserve blood flow to liver -Produce effective decompression of varices -Preservation of some residual portal hypertension
Partial shunt Small diameter (8 -10 mm) prosthetic graft placed between IVC and Portal vein
DEVASCULARISATION PROCEDURES • Aim : To disconnect venous drainage of stomach and oesophagus from liver and intestinal vessels • It prevents variceal bleeding by interrupting inflow into the varices • Portal flow to the cirrhotic liver is maintained • Most effective procedure : Sugiura procedure
• Originally a combined abdominal & thoracic procedure • Now mainly done as an abdominal procedure • Devascularisation -Whole of greater curvature of stomach -Atleast 7 cm of distal oesophagus -Upper 2/3 rd of lesser curvature of stomach
Sugiura procedure Oesophageal transection, esophagogastric devascularisation, splenectomy and either SV with pyloroplasty or HSV without pyloroplasty
Sugiura procedure • Useful when patients have extensive portal & splenic vein thrombosis & no other operative or radiologic options are available
Hepatic transplantation • Indication : Non alcoholic cirrhotic patients and abstinent alcoholic cirrhotic patients with either limited hepatic reserve (Child’s class B and C) or a poor quality of life secondary to their disease after controlling acute hemorrhage
Management Stratergies • Prophylaxis • Acute Variceal Bleed • Prevention of Rebleeding
PROPHYLAXIS -Beta blockers should be used - Bleeding is reduced from 30% to 18 -20%
• ACUTE VARICEAL BLEED Overall managementü Airway protection ü Appropriate fluid resuscitation ü Adequate monitoring ü Antibiotic prophylaxis ü Transfusion of blood for bleeding ü Blood products for coagulopathy
• Pharmacologic therapy with octreotide • Early endoscopy • Baloon tamponade in patients who cant undergo banding • Emergency TIPS is rarely used
Prevention of rebleeding • Variceal banding + pharmacotherpy – 1 st line • Banding should be performed within 1 st 4 to 5 days of acute bleed • Good risk patient(Child A or MELD <10) • Indeterminate patient(Child’s B or MELD 1016) • End stage liver disease(Childs C or MELD >16)
Acute Variceal Bleed
Algorithm for definitive therapy of variceal hemorrhage
Ascites
Ascites • Pathogenesis : Altered hepatic and splanchnic hemodynamics cause transudation of fluid into interstitial space When the rate of interstitial fluid formation exceeds the lymph drainage capacity, ascites accumulates • Indicator of Advanced liver disease
Ascites-Treatment • Salt restriction (20 -30 m. Eq/day) + Spironolactone 100 -400 mg/day) – First line of treatment • Loop diuretics can be added if above regimen fails. • Intermittent abdominal paracentesis +/- colloid infusion also effective. • Refractory cases – Surgery • Peritoneovenous shunt – rarely used because of increased morbidity • Side to side portocaval shunt or TIPS can be done
Encephalopathy • Portosystemic encephalopathy may have a variety of manifestations, including ü alterations in the level of consciousness, ü intellectual deterioration, ü personality changes, and ü neurologic findings such as the flapping tremor, asterixis. • They occur in patients with either significant hepatocellular dysfunction or portosystemic shunting.
• Pathogenesis of encephalopathy are based on circulating cerebral toxins that are intestinally absorbed and bypass the liver by means of shunts or fail to be inactivated by the liver's decreased metabolic capacity. • Cerebral toxins include ammonia, mercaptans, and γ-aminobutyric acid. • These substances are normally derived from the intestine & detoxified in the liver
• Key to the management of encephalopathy is identifying and then eliminating whatever precipitating factors are responsible. • Dietary protein is restricted, • Infections are treated, • All sedatives are discontinued, and • Intestinal catharsis is accomplished
Treatment • Treatment or removal of precipitating cause • Correct electrolyte imbalance • Eliminate dietary protiens to suppress production of neurotoxins by the bacteria in the bowel
Treatment • The only drugs with proven effectiveness are neomycin, a poorly absorbed antibiotic that suppresses urease-containing bacteria, and • Lactulose, a nonabsorbable disaccharide that acidifies colonic contents and also has a cathartic effect. • A likely mechanism of action of both of these drugs is a decrease in the amount of intestinal ammonia and inhibition of its absorption. • Neomycin is administered orally in a dose of 1. 5 g every 6 hours. • In the acute setting, lactulose is given in a dose of 30 g every 1 or 2 hours until a cathartic effect is noted. .
CONCLUSION q. Surgical intervention becoming a rarity except in those with end stage liver disease q. With the advent of TIPS indications for surgical shunts decreasing q. Choice of a surgical procedure depends most importantly on expertise of surgeon
- Slides: 122